Brind.

Beam Therapeutics Achieves Primary Efficacy Endpoint for Sickle Cell Therapy

1 report, 1 independent Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Beam Therapeutics announced positive topline results from the BEACON Phase 1/2 study evaluating ristoglogene autogetemcel (risto-cel) for sickle cell disease. The study achieved the primary efficacy endpoint of freedom from severe vaso-occlusive crises for at least 12 consecutive months and met all primary safety endpoints. These results support a planned U.S. Biologics License Application (BLA) submission, expected as early as Year-End 2026.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The positive clinical outcomes for risto-cel could support the planned BLA submission to the FDA, potentially moving the therapy closer to market availability. This progress is notable as Beam Therapeutics and CRISPR Therapeutics are competing in the gene-editing space for blood disorders.

From manilatimes.net

Who's involved

  • Beam TherapeuticsBiotechnology company developing precision genetic medicines
  • FDARegulates Beam Therapeutics and grants clearances for drug candidates
  • CRISPR TherapeuticsCompetes with Beam Therapeutics in the gene-editing space
  • Ark InvestActively purchasing or increasing its investment stake in Beam Therapeutics

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped